Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
1.
Oral Oncol ; 43(1): 51-9, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16798062

ABSTRACT

We investigated the expression of CD44 and MMP-9 in primary oral squamous cell carcinoma (OSCC) and evaluated their association with each other and clinicopathological factors as well as their prognostic value during long term follow up. Histological samples from 138 OSCC patients were immunohistochemically stained for the expression of CD44 and MMP-9. The staining results were compared with conventional prognostic factors and their impacts to patients' prognosis were also studied with survival analyses. Irregular staining of CD44 in tumour cells was associated with poor tumour differentiation (p=0.003), higher clinical stage (III-IV) (p=0.049), and the presence of T3-4 tumour stage (p=0.03). Strong stromal MMP-9 staining intensity was correlated with poor tumour differentiation (p=0.03). In univariate survival analysis irregular staining of CD44 in tumour cells was related to poor disease free and overall survival (p=0.001 and p<0.001, respectively). In multivariate analysis CD44 staining was a significant independent predictor for overall (p=0.03) and disease free survival (p=0.003). MMP-9 expression showed no statistical significance in survival analyses. Strong stromal staining intensity of MMP-9 correlated with irregular staining of CD44 in tumour cells, but had no prognostic significance in the present cohort. However, irregular staining of CD44 predicted more advanced disease and shortened survival of the patients.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/metabolism , Hyaluronan Receptors/metabolism , Matrix Metalloproteinase 9/metabolism , Mouth Neoplasms/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Child , Disease-Free Survival , Female , Humans , Immunohistochemistry , Male , Middle Aged , Mouth Neoplasms/pathology , Multivariate Analysis , Prognosis
2.
J Clin Pathol ; 57(7): 735-9, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15220367

ABSTRACT

AIMS: To study the expression of versican, a large proteoglycan involved in repressing adhesion between cells and the extracellular matrix in pharyngeal squamous cell carcinoma (PSCC), and its relation to the expression of p53 and catenins, histological differentiation, clinical data, and prognosis. METHODS: For the retrospective survey, primary tumours for analyses were obtained from 118 patients diagnosed with PSCC of the oropharynx or hypopharynx. The immunohistochemical expression of versican was studied and was related to the expression pattern of p53 and catenins, in addition to clinical data and survival. RESULTS: In the primary tumours, strong stromal versican expression was graded as low in 59 (50%) and high in 59 (50%) cases. In addition, intracellular versican staining was seen in nine (8%) tumours. In local lymph node metastases, strong stromal versican staining was significantly more frequent compared with the primary tumours (p = 0.018). Strong stromal versican staining was more frequently seen in less advanced tumours (p = 0.015). There was no association between versican expression and the other investigated variables (p53, catenins, TNM status, and histological grade). Neither stromal nor intracellular versican expression predicted overall survival in these patients. CONCLUSIONS: Versican was more strongly expressed in the stroma of local metastases and in the earlier stages of disease in PSCC. However, versican expression was not an independent prognostic factor in this entity.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/metabolism , Chondroitin Sulfate Proteoglycans/metabolism , Pharyngeal Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Analysis of Variance , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Female , Humans , Immunoenzyme Techniques , Lectins, C-Type , Male , Middle Aged , Neoplasm Proteins/metabolism , Neoplasm Staging , Pharyngeal Neoplasms/pathology , Pharyngeal Neoplasms/therapy , Prognosis , Retrospective Studies , Treatment Outcome , Tumor Suppressor Protein p53/metabolism , Versicans
3.
Oral Oncol ; 40(3): 257-63, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14747056

ABSTRACT

Several malignant tumours accumulate hyaluronan (HA), a matrix component suggested to promote cancer cell growth and migration. The expression and prognostic value of HA was analysed in a cohort of 151 oral squamous cell carcinoma (SCC) patients with adequate archival tumour material and follow-up data. The tumour samples were stained using a biotinylated HA-specific probe. Normal squamous epithelium showed a strong and homogeneously distributed staining for HA. The most superficial layers were HA-negative. In moderate (n=11) and high grade (n=16) dysplasias an irregular HA staining was observed around invasive cancer. Malignant transformation in oral squamous cell epithelium changed the staining toward irregular with focal reduction of HA. The well (n=92) or moderately differentiated (n=47) carcinomas had a strong HA staining intensity. In poorly differentiated tumours (n=12) the HA staining was weaker and mainly intracellular. The stromal tissue showed usually moderate (n=69) or strong (n=67) HA staining intensity with no statistically significant correlation with the degree of tumour differentiation. At the end of the follow-up (median 52 months) 66 (43%) patients had died because of an oral SCC. A significant difference in overall survival (OS) and disease free survival (DFS) (P=0.0002 and 0.0020, respectively) was noticed between the patients with the different epithelial staining patterns for HA. The reduction of HA staining was associated with poor survival. In Cox's multivariate analysis HA staining was a significant independent predictor of OS (P=0.011) and DFS (P=0.013). These results suggest that HA is a prognostic marker in oral squamous cell carcinoma.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/metabolism , Hyaluronic Acid/metabolism , Mouth Neoplasms/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Child , Epidemiologic Methods , Female , Humans , Male , Middle Aged , Mouth Mucosa/metabolism , Mouth Neoplasms/pathology , Neoplasm Staging , Prognosis
4.
Eur J Cancer ; 39(8): 1115-20, 2003 May.
Article in English | MEDLINE | ID: mdl-12736111

ABSTRACT

This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with recombinant interferon alpha-2b. The dose of bleomycin was 15 mg on days 2 and 5, of vincristine 1 mg/m(2) on days 1 and 4, of lomustine 80 mg on day 1, and of dacarbazine (DTIC) 200 mg/m(2) on days 1-5, given every 4 weeks for a minimum of two cycles. Subcutaneous (s.c.) interferon alpha-2b at a dose of 3 x 10(6) IU was initiated on day 8 of the first cycle, and continued at a dose of 6 x 10(6) IU three times per week after 6 weeks. A median of two cycles were administered to 24 patients (median age 60.5 years). None achieved an objective response (0%; 95% Confidence Interval (CI): 0-14), 2 (8.3%) remained stable, 20 showed progression, and 2 (8.3%) were invaluable. The median progression-free survival was 1.9 months (95% CI: 1.8-3.4) and overall survival 10.6 months (95% CI: 6.9-16.4). Overall survival improved with increasingly favourable pretreatment characteristics (median, 14.7 versus 6.9 versus 6.0 months for Helsinki University Central Hospital (HUCH) Working Formulation stages IVBa, IVBb and IVBc, respectively; P=0.018). Grade 3 alopecia and neurotoxicity occurred in 13% of the patients. This multicentre study did not confirm earlier reports that BOLD with human leucocyte or recombinant interferon would induce at least 15% objective responses in metastatic uveal melanoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Melanoma/drug therapy , Neoplasm Metastasis/drug therapy , Uveal Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bleomycin/administration & dosage , Bleomycin/adverse effects , Dacarbazine/administration & dosage , Dacarbazine/adverse effects , Disease-Free Survival , Feasibility Studies , Female , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Lomustine/administration & dosage , Lomustine/adverse effects , Male , Middle Aged , Prospective Studies , Recombinant Proteins , Treatment Outcome , Vincristine/administration & dosage , Vincristine/adverse effects
5.
Eur J Cancer ; 38(13): 1717-23, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12175687

ABSTRACT

This study aimed to examine the clinical and biological differences in 198 patients with either T1-T2 local glottic or supraglottic squamous cell carcinomas. The patients with supraglottic cancer had a poorer prognosis, as well as more advanced and histologically aggressive tumours than the patients with glottic tumours. They also had lower levels of haemoglobin and a poorer nutritional and performance status. Expression of alpha-catenin, hyaluronan, CD44, p53, p21/WAF1 and bcl-2 in the primary tumour were not associated with the site of the laryngeal carcinoma. In supraglottic tumours, the rate of spontaneous apoptosis and mitotic indices were significantly higher than in glottic tumours. The results suggest that clinical parameters including the haemoglobin level of the patient together with the tumour cell kinetics (mitotic and apoptotic rates) may contribute to the aggressive nature of supraglottic carcinoma.


Subject(s)
Carcinoma, Squamous Cell/pathology , Glottis , Laryngeal Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/metabolism , Female , Follow-Up Studies , Humans , Hyaluronan Receptors/metabolism , Laryngeal Neoplasms/radiotherapy , Laryngeal Neoplasms/surgery , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Prognosis , Proto-Oncogene Proteins c-bcl-2/metabolism , Tumor Suppressor Protein p53/metabolism
6.
Eur J Cancer ; 37(13): 1629-34, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11527688

ABSTRACT

Cell adhesion molecules are cell surface glycoproteins that may act as mediators in the metastatic process. Soluble interleukin-2 receptor (sIL-2R) is an immunological marker that may also serve as an indicator of tumour progression. Normal and neoplastic cells are capable of releasing these molecules into circulation. We evaluated the association between pretreatment serum levels of soluble intercellular adhesion molecule 1 (sICAM-1), vascular cell adhesion molecule 1 (sVCAM-1) and sIL-2R and metastases and survival in 50 patients with advanced melanoma. The patients with liver and/or bone metastases had significantly higher sICAM-1 levels than those with soft tissue and/or lung involvement (P=0.002). In addition, there was a trend towards higher sIL-2R levels in patients with more metastatic sites (P=0.07). In univariate analysis, the number of metastatic sites (P=0.0001, odds ratio (OR) 3.0, 95% confidence interval (CI): 1.7-5.3), the metastatic site (P=0.01, OR 2.3, 95% CI: 1.2-4.4) and the levels of sICAM-1 (P=0.011, OR 2.5, 95% CI: 1.2-5.0), sVCAM-1 (P=0.036, OR 2.1, 95% CI: 1.0-4.3) and sIL-2R (P=0.0016, OR 3.0, 95% CI: 1.5-6.0) were found to be statistically significant prognostic factors for survival. In multivariate analysis, the number of metastatic sites was the dominant prognostic indicator. After it was excluded from the analysis, the sIL-2R level and the metastatic site were found to be significant. It can be concluded, that high sICAM-1 levels suggest liver metastases and sIL-2R seems to serve as a marker of tumour load in metastatic melanoma. Furthermore, the sIL-2R level appears to add to clinical data predicting the patient's outcome.


Subject(s)
Biomarkers, Tumor/metabolism , Intercellular Adhesion Molecule-1/metabolism , Melanoma/blood , Neoplasm Proteins/metabolism , Receptors, Interleukin-2/metabolism , Skin Neoplasms/blood , Vascular Cell Adhesion Molecule-1/metabolism , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/diagnosis , Bone Neoplasms/secondary , Disease-Free Survival , Female , Follow-Up Studies , Humans , Liver Neoplasms/diagnosis , Liver Neoplasms/secondary , Lung Neoplasms/diagnosis , Lung Neoplasms/secondary , Male , Melanoma/diagnosis , Melanoma/drug therapy , Middle Aged , Multivariate Analysis , Skin Neoplasms/diagnosis , Skin Neoplasms/drug therapy
7.
Breast Cancer Res Treat ; 67(2): 117-23, 2001 May.
Article in English | MEDLINE | ID: mdl-11519860

ABSTRACT

PURPOSE: We studied which, age of the patient or density of the breast accounts for the sensitivity of mammography and ultrasonography (US). Furthermore we studied whether the overall impression on the density of the breast or the density in tumour area accounts for the sensitivity of mammography and ultrasonography. MATERIALS AND METHODS: The material consisted of 572 consecutive histologically and 5 cytologically verified breast cancer cases. Mammography and US examinations were performed immediately before breast cancer operations and information on the findings were received from the original patient files and classified as malignant or benign. The density of breast parenchyma to fatty, mixed or dense in total breast and separately in tumour area was defined by a radiologist group from the original mammograms by comparing to model mammograms. The sensitivity (Se) of mammography and US was compared in 3 age groups (26-49, 50-59 and 60-92) and in the different density classes. RESULTS: Sensitivity of mammography increased by age (density-adjusted OR = 0.2, 95%, CI 0.1-0.5) in age group 26-49 compared to age group 60-92) and with fattiness of the breast (age-adjusted OR= 0.4, 95%, CI 0.1-1.0 for dense breast parenchyma in tumour area compared to fatty breast). Sensitivity of US was inversely related to age (density-adjusted OR = 2.3, 95%, CI 1.0-5.2 in age group 26-49 compared to age group 60-92) and directly related with fattiness of breast (age-adjusted OR = 0.5, 95%, CI 0.2-0.9 by dense breast parenchyma in tumour area compared to fatty breast). Density in the tumour area compared to total breast density was related only mariginally better sensitivity both of mammography (0.4 vs. 0.6) and of US (0.5 vs. 0.6). CONCLUSION: Sensitivity of both mammography and sensitivity of US are independently related both to the age of the patient and to the density of the breast. The effect of age is inverse and that of density parallel between mammography and US on sensitivity. The effect of overall breast density was close to the effect of density at the site of the tumour on the sensitivity of both mammography and US.


Subject(s)
Breast Neoplasms/diagnostic imaging , Breast/anatomy & histology , Mammography , Ultrasonography , Adult , Age Factors , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Sensitivity and Specificity
8.
J Clin Pathol ; 54(1): 42-7, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11271788

ABSTRACT

AIMS: To investigate the expression of alpha, beta, and gamma catenins in oropharyngeal and hypopharyngeal squamous cell carcinoma and their relations to each other, as well as to clinical data, tumour differentiation, and prognosis. METHODS: Primary tumours for analysis were obtained from 138 patients diagnosed with squamous cell carcinoma of the oropharynx or hypopharynx between 1975 and 1998 in eastern Finland. Immunohistochemistry was used to evaluate the expression of alpha, beta, and gamma catenins. The expression patterns of all catenins were related to clinical data and survival. RESULTS: The expression patterns of all three catenins were significantly interrelated. Reduced gamma catenin expression was significantly associated with poor histological differentiation. No association was found between alpha or beta catenin expression and clinicopathological characteristics. In univariate analysis, patients whose tumours had nuclear beta catenin expression had shorter overall survival than patients with no nuclear expression. In Cox multivariate analysis, nuclear beta catenin expression, tumour status (T class), and Karnofsky performance index were independent prognostic factors of overall survival. CONCLUSIONS: Reduced expression of gamma catenin is associated with dedifferentiation in primary squamous cell carcinoma of the oropharynx and hypopharynx. The fact that nuclear beta catenin expression independently predicts short overall survival suggests that it might be a valuable prognostic marker in pharyngeal squamous cell carcinoma.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/metabolism , Cytoskeletal Proteins/metabolism , Hypopharyngeal Neoplasms/metabolism , Oropharyngeal Neoplasms/metabolism , Trans-Activators , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Cell Differentiation , Cell Nucleus/metabolism , Female , Follow-Up Studies , Humans , Hypopharyngeal Neoplasms/pathology , Immunoenzyme Techniques , Karnofsky Performance Status , Male , Middle Aged , Neoplasm Proteins/metabolism , Oropharyngeal Neoplasms/pathology , Prognosis , Survival Rate , beta Catenin
9.
Head Neck ; 23(1): 29-33, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11190855

ABSTRACT

BACKGROUND: The pharyngocutaneous fistula is troublesome complication after total laryngectomy. Despite a large number of studies, there is still disagreement on factors predisposing to this complication. METHODS: A retrospective analysis of pharyngocutaneous fistulas in 133 patients in whom total laryngectomy was performed. RESULTS: Fistulas were found in 15% of the patients. Spontaneous closure was noted in 80%. Simultaneous laryngectomy and partial pharyngectomy or neck dissection increased the risk of fistula formation. Preoperative irradiation, short interval between radiotherapy and operation, and cobalt/roentgen radiation instead of photons predispose to this complication. The fistulas appeared earlier, and the sizes of fistulas were significantly larger in patients with previous irradiation than those in patients with no preoperative irradiation. CONCLUSIONS: Postoperative pharyngocutaneous fistulas significantly increase patients' morbidity and hospital stay. Good surgical technique and postoperative treatment should be paid attention to patients with an increased risk of pharyngocutaneous fistula formation.


Subject(s)
Cutaneous Fistula/etiology , Laryngectomy/adverse effects , Oral Fistula/etiology , Pharyngeal Diseases/etiology , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Female , Humans , Laryngeal Neoplasms/radiotherapy , Laryngeal Neoplasms/surgery , Male
10.
Clin Radiol ; 56(1): 40-3, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11162696

ABSTRACT

AIM: To study how many tumours were visible in restrospect on mammograms originally reported as normal or benign in patients coming to surgery with proven breast cancer. The effect of making the pre--operative mammogram available was also assessed. MATERIALS AND METHODS: Three hundred and twenty initial mammograms of consecutive new breast cancer cases were analysed by a group of radiologists in the knowledge that all patients were later diagnosed with breast cancer. The films were read twice, first without and then with the later (pre-operative) mammograms available. The parenchymal density in the location of the tumour was classified as fatty, mixed or dense, and the tumours were classified as visible or not visible. The reasons for the invisibility of the tumour in the earlier examination were analysed. RESULTS: Fourteen per cent (45) of cancers were retrospectively visible in earlier mammograms without the pre-operative mammograms having been shown, and 29% (95) when pre-operative mammograms were shown. Breast parenchymal density decreased with age and the visibility of tumours increased with age. When considered simultaneously, the effect of age (over 55 vs under 55) was greater (OR = 2.9) than the effect of density (fatty vs others) (OR = 1.5). The most common reasons for non-detection were that the lesion was overlooked (55%), diagnosed as benign (33%) or was visible only in one projection (26%). Growing density was the most common (37%) feature of those lesions originally overlooked or regarded as benign. CONCLUSIONS: Tumours are commonly visible in retrospect, but few of them exhibit specific signs of cancer, and are recognized only if they grow or otherwise change. It is not possible to differentiate most of them from normal parenchymal densities. Saarenmaa, I. (2001). Clinical Radiology56, 40-43.


Subject(s)
Breast Neoplasms/diagnostic imaging , Diagnostic Errors , Mammography , Adult , Age Factors , Aged , False Negative Reactions , Female , Humans , Middle Aged , Retrospective Studies , Time Factors
11.
Anticancer Res ; 21(6A): 4185-8, 2001.
Article in English | MEDLINE | ID: mdl-11911316

ABSTRACT

BACKGROUND: The purpose of this study was to analyse the results of salvage surgery after failure of irradiation to control the primary T1-T2 glottic cancer. MATERIALS AND METHODS: Ninety-eight patients with T1 and T2 squamous cell cancer of the glottic larynx were treated with curative intent by radiotherapy. The tumour recurred in 22 of the 98 (22%) patients. Surgical management consisted of total and frontolateral laryngectomy. Survival rates were calculated from the date of the salvage operation. RESULTS: Two of the 22 patients refused to undergo salvage surgery and one patient had pulmonary metastasis. Of the 19 patients who underwent salvage surgery, 14 (74%) had total laryngectomy and 5 (26%) had frontolateral laryngectomy. The operations were curative in 15 (79%) of the 19 patients. The overall 5-year survival rate after surgery was 78%. CONCLUSION: Stringent follow-up of patients with irradiated T1 and T2 glottic laryngeal cancer is essential to permit a successful salvage.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Laryngeal Neoplasms/radiotherapy , Laryngeal Neoplasms/surgery , Neoplasm Recurrence, Local/surgery , Carcinoma, Squamous Cell/pathology , Humans , Laryngeal Neoplasms/pathology , Neoplasm Staging , Salvage Therapy , Treatment Failure
12.
Breast ; 10(1): 78-81, 2001 Feb.
Article in English | MEDLINE | ID: mdl-14965565

ABSTRACT

By studying which radiological examinations had been performed before breast cancer operations the aim was to assess, how much benefit ultrasonography (US) and fine or core needle biopsy (FNAB, CNB) gave in addition to mammography, and whether the sensitivity of these examinations varied with the age of the patient. There were 659 consecutive histologically and six cytologically verified breast cancer cases included in the study. Information on mammography, US and FNAB findings were retrieved from the original patient files and classified as malignant or benign. The sensitivity (Se) of these was compared in three age groups (26-49, 50-59 and 60-92). Seventeen (3%) tumours had operations without any radiological examination and 73 (11%) without cytological or histological verification. The sensitivity of mammography (Se=0.92) was statistically significantly higher than the sensitivity of FNAB (Se=0.85, P=0.002) or US (Se=0.86, P=0.003). The sensitivity of mammography increased with age; US sensitivity was slightly higher amongst younger than older patients; the sensitivity of FNAB did not depend on the age of the patient. The sensitivity using a cutoff level of class 5 for mammography was higher (50% typical malignant findings) than for US (45%) or FNAB (30%). Among cases with benign mammographic finding (classes 1-2), the US finding was malignant (classes 3-5) in 4% and FNAB was malignant in 7%. Mammography is a reliable method of breast examination especially for women over 50 years of age. Ultrasonography is beneficial, particularly in younger women, but it is mainly performed as a complementary examination to a mammography and therefore could not be evaluated as an independent examination. FNAB and CNB results were not related to the age of the patient.

13.
Radiother Oncol ; 57(1): 97-101, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11033194

ABSTRACT

PURPOSE: To investigate the incidence of hypothyroidism after radiotherapy of laryngeal cancer, including the possible factors that could predict the onset of hypothyroidism. MATERIALS AND METHODS: We report this study on patients treated by radiotherapy as part of the treatment for laryngeal cancer in the Department of Oncology in Eastern Finland. Sixty-five males and seven females were treated with radiotherapy between 1974-1995.Thyroid function was determined by measuring serum thyroid stimulating hormone, and serum free thyroxine (FT4). The studied risk factors for hypothyroidism included age, treatment modalities, radiation dose and energy, height of the radiation field, and follow-up time. RESULTS: Hypothyroidism was detected in 17 (24%) of the 72 patients. Hypothyroidism was clinically unsuspected in all but one patient. Hypothyroidism was more common, if the height of the radiation field was >/=7 cm, or the patient had been operated. Hypothyroidism was less common if less than a half of the thyroid bed was irradiated. CONCLUSION: The detection of hypothyroidism clinically is difficult, and the rate of hypothyroidism warrants routine assessment of thyroid function after irradiation of laryngeal cancer.


Subject(s)
Hypothyroidism/etiology , Laryngeal Neoplasms/radiotherapy , Radiotherapy/adverse effects , Thyroid Gland/radiation effects , Adult , Aged , Aged, 80 and over , Cohort Studies , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Female , Humans , Hypothyroidism/diagnosis , Hypothyroidism/epidemiology , Incidence , Laryngeal Neoplasms/drug therapy , Laryngeal Neoplasms/surgery , Male , Middle Aged , Prognosis , Radiation Tolerance , Radiotherapy Dosage , Risk Factors , Thyroid Function Tests
14.
Melanoma Res ; 10(3): 237-41, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10890377

ABSTRACT

Recently serum S-100beta has shown promise as a tumour marker in melanoma; however, its use as a prognostic marker in the advanced stage needs to be confirmed. Interleukins (ILs) may mediate regression or progression of cancer. In order to study their relation to the metastatic profile and survival, we evaluated the association between pretreatment serum levels of S-100beta, IL-6, IL-10 and IL-12 and metastatic site and survival in 50 patients with advanced melanoma who were to receive chemoimmunotherapy. Patients with liver and/or bone metastases had significantly higher median concentrations of S-100beta, IL-6 and IL-10 than those with only skin, nodal and/or lung involvement. The differences in IL-12 levels were unremarkable. Using univariate analysis, the S-100beta level and metastatic profile were found to be statistically significant prognostic factors for survival. Using multivariate analysis the S-100beta level was the most powerful prognostic indicator, while the metastatic profile was found to be significant after exclusion of S-100beta. The findings suggest that elevated serum levels of S-100beta, IL-6 and IL-10 reflect concurrent liver or bone metastases in melanoma. S-100beta is also an independent prognostic marker. Pretreatment IL levels were not associated with outcome.


Subject(s)
Biomarkers, Tumor/blood , Interleukins/blood , Melanoma/blood , S100 Proteins/blood , Skin Neoplasms/blood , Adult , Aged , Antineoplastic Agents/therapeutic use , Bone Neoplasms/blood , Bone Neoplasms/secondary , Humans , Immunotherapy , Interferon-alpha/metabolism , Liver Neoplasms/blood , Liver Neoplasms/secondary , Lymphatic Metastasis , Melanoma/mortality , Melanoma/secondary , Melanoma/therapy , Middle Aged , Neoplasm Staging , Prognosis , Prospective Studies , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Survival Rate
15.
Acta Oncol ; 39(7): 877-9, 2000.
Article in English | MEDLINE | ID: mdl-11145448

ABSTRACT

The association was studied between serum concentration of matrix metalloproteinase-2 (MMP-2) and metastatic site, survival and disease progression in patients with advanced cutaneous melanoma. The patient population consisted of 50 patients who were treated with chemoimmunotherapy. The median baseline serum concentration of MMP-2 was 724 ng/ml (range 500-2,297 ng/ml). There were no significant differences in MMP-2 levels according to metastatic site. Baseline MMP-2 concentration did not have a prognostic value. The patients with levels below 800 ng/ml survived for 8.8 months and those with higher levels for 9.7 months. On serial measurements, median serum MMP-2 concentration at disease progression in 25 patients was significantly higher than before treatment. Only five samples at response were available, and the levels were not significantly different from baseline levels. In conclusion, serum MMP-2 is not a prognostic marker in advanced melanoma. It also appears to be of limited clinical value in monitoring.


Subject(s)
Biomarkers, Tumor/analysis , Matrix Metalloproteinase 2/blood , Melanoma/enzymology , Skin Neoplasms/enzymology , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disease Progression , Female , Humans , Immunotherapy , Male , Matrix Metalloproteinase 2/metabolism , Melanoma/pathology , Melanoma/therapy , Middle Aged , Prognosis , Sensitivity and Specificity , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Survival Analysis
16.
Eur Arch Otorhinolaryngol ; 257(10): 558-60, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11195037

ABSTRACT

Merkel cell carcinoma is a rare, although increasingly recognized, malignant tumor of the skin. The most common site of occurrence is the head and neck (50%). Only five cases of this tumor on the auricle have been reported previously. We present a further such case. The incidence, clinical features, diagnosis, prognosis, and treatment of the Merkel cell carcinoma are discussed.


Subject(s)
Carcinoma, Merkel Cell/diagnosis , Ear Neoplasms/diagnosis , Ear, External , Aged , Aged, 80 and over , Carcinoma, Merkel Cell/pathology , Carcinoma, Merkel Cell/surgery , Diagnosis, Differential , Ear Neoplasms/pathology , Ear Neoplasms/surgery , Ear, External/pathology , Ear, External/surgery , Humans , Male
17.
Acta Oncol ; 39(1): 77-9, 2000.
Article in English | MEDLINE | ID: mdl-10752658

ABSTRACT

In Finland traditionally as many as two-thirds of laryngeal cancers have been considered to be supraglottic, while in other countries the majority are glottic. The Finnish observation is based on clinical series diagnosed and treated mainly before the 1960s. The aim of our study was to evaluate the present situation. This study consisted of 279 patients treated in Eastern Finland between 1975 and 1994 and included 145 (52%) glottic, 124 (44%) supraglottic and 10 (4%) subglottic tumours in 260 (93%) men and 19 (7%) women. During this study period, the proportion of glottic tumours remained stable in men but increased in women. The change in smoking habits seems to be the most important reason for the shift from supraglottic to glottic tumours.


Subject(s)
Glottis/pathology , Laryngeal Neoplasms/pathology , Smoking/adverse effects , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Finland/epidemiology , Humans , Incidence , Laryngeal Neoplasms/etiology , Male , Middle Aged , Smoking/epidemiology
18.
J Clin Pathol ; 52(6): 440-4, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10562812

ABSTRACT

AIM: To analyse p21/WAF1 expression and its relation to p53, apoptosis, cell proliferation, clinicopathological characteristics, and patient survival in human laryngeal squamous cell carcinoma. METHODS: Primary tumours for analyses were obtained from 172 patients with complete follow up data. All patients were treated between 1975 and 1995. Immunohistochemistry was used to evaluate the expression of p21/WAF1, bcl-2, and p53 proteins. The proliferative activity was determined using Ki67 and PCNA antibodies as well as volume corrected mitotic count (M/V index). Volume corrected apoptotic count (A/V index) was determined using an enzymatic in situ cell death detection kit based on the TUNEL method. RESULTS: High p21 expression was significantly related to high p53 and normal bcl-2 expressions as well as low mitotic count. No association was noticed between p21 expression and apoptotic rate. A significant inverse correlation between p21 expression and advanced stage and poor differentiation was observed, but p21 expression showed no correlation with survival. CONCLUSIONS: The expression of p21 was associated with tumour stage, histopathological grade, node status, and mitotic count, which may indicate a role for p21 in the progression of laryngeal squamous cell carcinoma.


Subject(s)
Carcinoma, Squamous Cell/genetics , Cyclins/genetics , Gene Expression Regulation, Neoplastic , Genes, Tumor Suppressor , Laryngeal Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Apoptosis , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Cyclin-Dependent Kinase Inhibitor p21 , Female , Genes, bcl-2 , Genes, p53 , Humans , Immunohistochemistry , In Situ Nick-End Labeling , Laryngeal Neoplasms/mortality , Laryngeal Neoplasms/pathology , Lymph Nodes/pathology , Male , Middle Aged , Mitotic Index , Neoplasm Staging , Prognosis , Survival Rate
19.
Eur J Cancer ; 35(2): 231-7, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10448265

ABSTRACT

The purpose of the current study was to analyse apoptosis and bcl-2 expression in laryngeal squamous cell carcinoma (SCC) with special reference to their prognostic significance, correlation with the clinical and pathological characteristics as well as cell proliferation and p53 accumulation. 172 patients with primary laryngeal SCC were followed-up for a median of 67 months. The volume corrected apoptotic (A/V) index was analysed using an in situ end labelling method (TUNEL) in 85 randomly selected patients. The expression of bcl-2 and p53 was analysed with monoclonal antibodies. The proliferative activity was measured both with Ki-67 (MIB-1) antibody and the volume corrected mitotic (M/V) index. The A/V index was not associated with p53 (P = 0.6) or bcl-2 (P = 0.6) expression or with proliferative parameters (P = 0.9 for M/V and P = 0.3 for MIB-1). The 10-year overall survival in patients with a high A/V index was poorer when compared with patients with a low index (47% versus 81%, P = 0.005), while accumulation of bcl-2 had no prognostic significance (P = 0.5). In Cox multivariate analysis of the whole cohort, stage (P < 0.0005) and histological grade (P = 0.04) were predictors of overall survival. In the subset of patients with an A/V index available, predictors of survival were stage (P = 0.05), A/V index (P = 0.02) and histological grade (P = 0.04). A high A/V index was an independent predictor of poor survival in laryngeal SCC. This effect was not associated with tumour cell proliferation. Accumulations of p53 and bcl-2 were not associated with apoptosis. Expression of bcl-2 lacks any prognostic significance in laryngeal SCC. We propose that assessment of the A/V index may help in selecting patients with poor prognosis.


Subject(s)
Carcinoma, Squamous Cell/pathology , Genes, bcl-2/genetics , Genes, p53/genetics , Laryngeal Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Apoptosis , Carcinoma, Squamous Cell/genetics , Cell Division , Cohort Studies , Female , Humans , Immunohistochemistry , Laryngeal Neoplasms/genetics , Male , Middle Aged , Prognosis , Retrospective Studies , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...